Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

8.700 -1.300 (-13.00%)
Streaming Delayed Price Updated: 10:21 AM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Fulcrum Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Earnings Scheduled For May 1, 2025
 
Via Benzinga
Earnings Scheduled For February 25, 2025
 
Via Benzinga
Expert Ratings For Fulcrum Therapeutics
 
Via Benzinga
Earnings Scheduled For October 29, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their outstanding shares is at $5.6 million. 
Via Benzinga
Small-Cap Stocks: An Undervalued Opportunity in a Cautious Market?
In a financial landscape increasingly dominated by the towering valuations of large-cap technology giants, a quieter, yet potentially profound, narrative is unfolding within the small-cap segment of... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Earnings Scheduled For November 13, 2024
 
Via Benzinga
Earnings Preview: Fulcrum Therapeutics
 
Via Benzinga
Fulcrum Therapeutics's Earnings Outlook
 
Via Benzinga
Breaking Down Fulcrum Therapeutics: 7 Analysts Share Their Views
 
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Monday?
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Uncovering Potential: Fulcrum Therapeutics's Earnings Preview
 
Via Benzinga
Which stocks are moving before the opening bell on Tuesday?
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal
MyoKardia, a Bristol Myers unit, is terminating its agreement with Fulcrum Therapeutics, ending a cardiomyopathy research deal set to expire in June 2025. 
Via Benzinga
These stocks are moving in today's pre-market session
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
Via Investor's Business Daily
Wall Street's Top 10 Stock Calls This Week - Saturday, Sept. 14
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Sept. 9-13, 2024. 
Via Talk Markets
Dow Surges Over 100 Points; ModivCare Shares Plummet
 
Via Benzinga
Topics Stocks
Crude Oil Surges 3%; Kroger Posts Upbeat Earnings
 
Via Benzinga
Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial
Fulcrum Therapeutics stock drops after Phase 3 REACH trial of losmapimod flops in Facioscapulohumeral Muscular Dystrophy. The company consider suspending the program. 
Via Benzinga
US Stocks Mixed; Producer Prices Increase In August
 
Via Benzinga
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystrophy, boosting the price target from $5 to $10 due to increased confidence in... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.